{
    "root": "2fb03673-b648-5b02-e063-6294a90a02f8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Extended Phenytoin Sodium",
    "value": "20250306",
    "ingredients": [
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "HYPROMELLOSE 2910 (4000 MPA.S)",
            "code": "RN3152OP35",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM OXIDE",
            "code": "3A3U0GI71G",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31794"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PHENYTOIN SODIUM",
            "code": "4182431BJH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_233284"
        }
    ],
    "indications": {
        "text": "extended phenytoin sodium capsules indicated treatment tonic-clonic ( grand mal ) psychomotor ( temporal lobe ) seizures prevention treatment seizures occurring following neurosurgery .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "adult starting dose patients received previous treatment one 100 mg extended phenytoin sodium capsule three times day , dose adjustments necessary . adults , satisfactory maintenance dose one capsule three four times day . increase , two capsules three times day may made , necessary . ( 2.1 ) adult once-a-day dose : seizure control established divided doses three 100 mg extended phenytoin sodium capsules daily , once-a-day 300 mg extended phenytoin sodium capsules may considered . ( 2.1 ) adult loading dose : reserved patients clinic hospital setting require rapid steady-state serum levels intravenous desired . refer full prescribing information . ( 2.1 ) pediatric starting dose 5 mg/kg/day two three equally divided doses , adjustments necessary , maximum 300 mg daily . maintenance 4 8 mg/kg/day . ( 2.2 ) serum blood level determinations may necessary optimal adjustments\u2014the clinically effective serum total concentration 10 20 mcg/ml ( unbound phenytoin concentration 1 2 mcg/ml ) . ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "extended phenytoin sodium capsules usp , 100 mg white/white , size \u2018 2 \u2019 hard gelatin capsule filled white off-white powder imprinted \u2018 x \u2019 white cap \u2018 51 \u2019 white body black ink . ndc : 70518-2227-00 ndc : 70518-2227-01 ndc : 70518-2227-02 ndc : 70518-2227-03 ndc : 70518-2227-04 ndc : 70518-2227-05 packaging : 30 1 blister pack packaging : 100 1 box packaging : 1 1 pouch packaging : 30 1 blister pack packaging : 100 1 box packaging : 1 1 pouch store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] . preserve tight , light-resistant containers . protect moisture . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "phenytoin sodium contraindicated patients : history hypersensitivity phenytoin , inactive ingredients , hydantoins [ ( 5.5 ) ] . included angioedema . history prior acute hepatotoxicity attributable phenytoin [ ( 5.8 ) ] . coadministration delavirdine potential loss virologic response possible resistance delavirdine class non-nucleoside reverse transcriptase inhibitors .",
    "indications_original": "Extended phenytoin sodium capsules are indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.",
    "contraindications_original": "Adult starting dose in patients who have received no previous treatment is one 100 mg extended phenytoin sodium capsule three times a day, with dose adjustments as necessary. For most adults, the satisfactory maintenance dose will be one capsule three to four times a day. An increase, up to two capsules three times a day may be made, if necessary. ( 2.1 ) Adult once-a-day dose: If seizure control is established with divided doses of three 100 mg extended phenytoin sodium capsules daily, once-a-day dosage with 300 mg extended phenytoin sodium capsules may be considered. ( 2.1 ) Adult loading dose: reserved for patients in a clinic or hospital setting who require rapid steady-state serum levels and where intravenous administration is not desired. Refer to full prescribing information. ( 2.1 ) Pediatric starting dose is 5 mg/kg/day in two to three equally divided doses, with dosage adjustments as necessary, up to a maximum of 300 mg daily. Maintenance dosage is 4 to 8 mg/kg/day. ( 2.2 ) Serum blood level determinations may be necessary for optimal dosage adjustments\u2014the clinically effective serum total concentration is 10 to 20 mcg/mL (unbound phenytoin concentration is 1 to 2 mcg/mL). ( 2.3 )",
    "warningsAndPrecautions_original": "Extended Phenytoin Sodium Capsules USP, 100 mg are white/white, size \u20182\u2019 hard gelatin capsule filled with white to off-white powder and imprinted with \u2018X\u2019 on white cap and \u201851\u2019 on white body with black ink.\n                  \n                  NDC: 70518-2227-00\n                  NDC: 70518-2227-01\n                  NDC: 70518-2227-02\n                  NDC: 70518-2227-03\n                  NDC: 70518-2227-04\n                  NDC: 70518-2227-05\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  PACKAGING: 100 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  \n                  \n                  \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature]. Preserve in tight, light-resistant containers. Protect from moisture.\n                  \n                  \n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Phenytoin sodium is contraindicated in patients with:\n                  \n                     A history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins\n  \n   [see\n   \n    Warnings and Precautions (5.5)]\n  \n   . Reactions have included angioedema.\n \n  \n                     A history of prior acute hepatotoxicity attributable to phenytoin\n  \n   [see\n   \n    Warnings and Precautions (5.8)].\n  \n   \n                     \n                     Coadministration with delavirdine because of the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.",
    "drug": [
        {
            "name": "Extended Phenytoin Sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8107"
        }
    ]
}